ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 26, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 2:30 p.m. Eastern Time.
David. R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be participating in the one-on-one meetings.
Presentation Date: |
Monday, May 2, 2022 |
Presentation Time: |
2:30 p.m. ET |
Location: |
Metro Toronto Convention Centre |
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.
A webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the presentation, the webcast will be archived for 90 days.
SOURCE ESSA Pharma Inc
Company Contact: Peter Virsik, Chief Operating Officer, ESSA Pharma Inc., Contact: (778) 331-0962, Email: [email protected]; Investor Relations Contact: Xuan Yang, Solebury Trout, Contact: (646) 378-2975, Email: [email protected]; Media Contact: Zara Lockshin, Solebury Trout, Contact: (646) 378-2960, Email: [email protected]
Share this article